What You Should Know:
– Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in C-2 funding led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech.
– Founded in 2014, the Variantyx proprietary whole genome sequencing and analysis platforms allow healthcare providers and their patients to better understand a person’s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations. The company’s precision oncology solution will use multiple genomic technologies to analyze and identify the unique genetic alterations in a patient’s tumor to help predict their response to various therapies, optimize management, as well as provide prognostic and clinical trials information.
– Variantyx plans use the funding to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.
